{"filing":{"accession_number":"0001171843-26-005479","cik":"0001581178","ticker":"EPRX","company_name":"EUPRAXIA PHARMACEUTICALS INC.","form":"6-K","filing_date":"2026-08-13","report_date":"2026-08-13","primary_document":"f6k_081326.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1581178/000117184326005479/f6k_081326.htm"},"events":[{"id":27541,"run_id":25110,"accession_number":"0001171843-26-005479","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"This press release announces positive interim clinical trial data from Eupraxia's Phase 1b/2a RESOLVE trial of EP-104GI for eosinophilic esophagitis, including new symptom response data on odynophagia and dysphagia, with no serious adverse events reported across 130+ patients. While the disclosure reports clinical progress rather than a discrete financial or governance event, the positive efficacy and safety data from an ongoing Phase 1b/2a trial represents a material operational/clinical milestone that would affect a reasonable investor's assessment of the company's drug development prospects and de-risking trajectory.","company_name":"EUPRAXIA PHARMACEUTICALS INC.","ticker":"EPRX","filing_date":"2026-08-13","form":"6-K","submitted_at":null,"items":[{"id":29121,"accession_number":"0001171843-26-005479","item_number":"EX-99.1","item_title":"exh_991.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This press release announces positive interim clinical trial data from Eupraxia's Phase 1b/2a RESOLVE trial of EP-104GI for eosinophilic esophagitis, including new symptom response data on odynophagia and dysphagia, with no serious adverse events reported across 130+ patients. While the disclosure reports clinical progress rather than a discrete financial or governance event, the positive efficacy and safety data from an ongoing Phase 1b/2a trial represents a material operational/clinical milestone that would affect a reasonable investor's assessment of the company's drug development prospects and de-risking trajectory.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-13T12:10:41.397246+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":29121,"accession_number":"0001171843-26-005479","item_number":"EX-99.1","item_title":"exh_991.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This press release announces positive interim clinical trial data from Eupraxia's Phase 1b/2a RESOLVE trial of EP-104GI for eosinophilic esophagitis, including new symptom response data on odynophagia and dysphagia, with no serious adverse events reported across 130+ patients. While the disclosure reports clinical progress rather than a discrete financial or governance event, the positive efficacy and safety data from an ongoing Phase 1b/2a trial represents a material operational/clinical milestone that would affect a reasonable investor's assessment of the company's drug development prospects and de-risking trajectory.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-13T12:10:41.397246+00:00","company_name":"EUPRAXIA PHARMACEUTICALS INC.","ticker":"EPRX","filing_date":"2026-08-13"}]}